A new study published in the journal The Lancet Oncology suggests that the GlaxoSmithKline's vaccine for cervical cancer is also effective in reducing the risk of anal cancer among women.
Researchers from the University of Missouri-Kansas City School of Medicine conducted the study to test the effectiveness of the vaccine, known as Cervarix, among more than 4,200 aged between 18 to 25 years in Costa Rica.
AdvertisementAfter four years, the researchers tested the participants for cervical and anal infections caused by various strains of the human papillomavirus (HPV) and found that those who were injected with Cervarix had a 76 percent lower chance of cervical cancer and a 62 percent lower risk of anal cancer compared to others.
P Sleeping With Contact Lenses Could Increase Risk of Blindness First Skin Cancer Treatment in Four Decades Gets European Approval M
You May Also Like